COMP <GO>
ADMA vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
ADMA Biologics Inc (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ADMA 8
— JNJ 4
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ADMA
LAST: $11.75 (+4.17%) • MKT CAP: $2.63B
balance-sheet
12.98
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADMA VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADMA | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.40% | 67.90% | -10.50 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 32.90% | 25.50% | +7.40 | ADMA | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.4x | 18.5x | -6.10 | ADMA | /valuation <GO> |
| Free Cash Flow Yield | 1.06% | 2.97% | -1.91 | JNJ | /fcf-yield <GO> |
| Operating Margin | 37.50% | 34.70% | +2.80 | ADMA | /operating-margins <GO> |
| Net Profit Margin | 28.80% | 28.50% | +0.30 | ADMA | /net-margins <GO> |
| Revenue Growth (YoY) | 19.60% | 6.00% | +13.60 | ADMA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 12.98 | 5.59 | +7.39 | ADMA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.9 | 62.1 | +5.80 | ADMA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.0x | 23.0x | -8.00 | ADMA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.63B | $662.49B | -$659.86B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADMA REV | JNJ REV | ADMA GROSS % | JNJ GROSS % | ADMA FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $510.2M | $94.19B | 57.4% | 67.9% | $27.8M | $19.70B |
| FY 2024 | $426.5M | $88.82B | 51.5% | 69.1% | $110.4M | $19.84B |
| FY 2023 | $258.2M | $85.16B | — | — | $8.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADMA // BETA —
JNJ // BETA 1.08